PSIL: 4th Quarter 2021 Portfolio Review
Performance data quoted represents past performance and is no guarantee of future results. Current performance may be lower or higher than the performance data quoted. Investment return and principal value will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than original cost. Returns less than one year are not annualized. For the fund’s most recent standardized and month-end performance, please click www.advisorshares.com/etfs/psil.
The AdvisorShares Psychedelics ETF (NYSE: PSIL) recently launched on September 15, 2021. In that short period since its launch, the Fund has had a loss of -44.18% on its net asset value (NAV) and -41.50% on its market price. For the 4th quarter, the Fund lost -38.13% on its net asset value (NAV) and -36.07% on its market price.
The Fund’s overall performance is tied to the success of the very new, small and volatile psychedelics industry – meaning biotech, pharmaceutical and mental health. We do aim for relative outperformance through good individual security selection and successful trading. While short term performance of these stocks has been down rather dramatically, we remain bullish on the longer-term prospects for this rapidly developing space.
As psychedelics has a limited universe of stocks, only one new addition was made to the portfolio during the quarter: Bright Minds Biosciences, (NASDAQ: DRUG). Over the course of these months since launch, we regularly added on to most positions as the Fund grew.
Contributors / Detractors:
For the 3½ month period since launch, basically all the securities in PSIL were down. In future quarters I expect to be able to offer a good discussion about the winners and losers in the portfolio.
|Ticker||Security Description||Portfolio Weight %|
|CMPS||COMPASS PATHWAYS PLC||11.09%|
|ATAI||ATAI LIFE SCIENCES NV||8.79%|
|MNMD||MIND MEDICINE MINDMED INC||8.60%|
|FTRP||FIELD TRIP HEALTH LTD||8.39%|
|GHRS||GH RESEARCH PLC||4.96%|
|SEEL||SEELOS THERAPEUTICS INC||4.79%|
|DMTTF||SMALL PHARMA INC||4.75%|
|DRUG||BRIGHT MINDS BIOSCIENCES INC||4.54%|
|NUMIF||NUMINUS WELLNESS INC||4.27%|
|GBNH||GREENBROOK TMS INC||4.19%|
As of 12.31.2021. Cash is not included. Subject to change.
Please see our complete Fund holdings at advisorshares.com/etfs/psil. The holdings details are updated each market day.